Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 10 04:00PM ET
7.24
Dollar change
+0.06
Percentage change
0.84
%
IndexRUT P/E- EPS (ttm)-2.73 Insider Own15.61% Shs Outstand52.00M Perf Week2.26%
Market Cap334.69M Forward P/E- EPS next Y-3.61 Insider Trans-0.50% Shs Float39.01M Perf Month-10.84%
Income-95.93M PEG- EPS next Q-0.84 Inst Own112.72% Short Float20.06% Perf Quarter-53.94%
Sales21.99M P/S15.22 EPS this Y-13.07% Inst Trans-20.82% Short Ratio8.69 Perf Half Y-68.91%
Book/sh10.63 P/B0.68 EPS next Y-23.78% ROA-29.90% Short Interest7.83M Perf Year-51.54%
Cash/sh10.86 P/C0.67 EPS next 5Y- ROE-33.00% 52W Range6.77 - 36.25 Perf YTD-64.26%
Dividend Est.- P/FCF- EPS past 5Y-46.35% ROI-16.75% 52W High-80.03% Beta2.74
Dividend TTM- Quick Ratio17.33 Sales past 5Y111.29% Gross Margin74.42% 52W Low6.94% ATR (14)0.53
Dividend Ex-Date- Current Ratio17.33 EPS Y/Y TTM17.81% Oper. Margin-477.24% RSI (14)40.08 Volatility6.35% 7.67%
Employees147 Debt/Eq0.04 Sales Y/Y TTM1014.45% Profit Margin-436.30% Recom1.64 Target Price45.70
Option/ShortYes / Yes LT Debt/Eq0.04 EPS Q/Q-2.15% Payout- Rel Volume0.53 Prev Close7.18
Sales Surprise-99.81% EPS Surprise-16.88% Sales Q/Q-98.74% EarningsNov 13 AMC Avg Volume901.21K Price7.24
SMA20-6.48% SMA50-13.22% SMA200-61.54% Trades Volume474,765 Change0.84%
Date Action Analyst Rating Change Price Target Change
Nov-21-24Initiated Morgan Stanley Underweight $8
Sep-23-24Downgrade Cantor Fitzgerald Overweight → Neutral
Apr-15-24Initiated Barclays Overweight $459
Apr-15-24Initiated Barclays Overweight $45
Feb-07-24Resumed Goldman Buy $81
Oct-26-23Initiated RBC Capital Mkts Outperform $25
Oct-24-23Initiated Cantor Fitzgerald Overweight $32
Oct-18-23Upgrade Leerink Partners Market Perform → Outperform $24
Jul-05-23Initiated Chardan Capital Markets Buy $30
Jan-30-23Initiated BMO Capital Markets Outperform $50
Nov-26-24 06:51AM
Nov-14-24 08:00AM
Nov-13-24 05:20PM
04:05PM
Sep-25-24 09:35AM
08:00AM Loading…
Sep-23-24 08:00AM
Sep-19-24 02:34PM
10:30AM
Sep-18-24 04:05PM
Sep-05-24 08:00AM
Sep-03-24 08:00AM
Aug-27-24 08:00AM
Aug-23-24 09:35AM
Aug-12-24 08:00AM
Aug-08-24 05:55PM
04:05PM Loading…
04:05PM
Aug-05-24 08:00AM
Jul-17-24 05:00AM
Jul-12-24 09:40AM
Jul-08-24 05:52PM
12:30PM
Jun-24-24 08:00AM
Jun-18-24 08:00AM
Jun-08-24 04:30PM
Jun-06-24 07:30AM
Jun-04-24 08:00AM
Jun-03-24 08:00AM
May-30-24 08:00AM
May-10-24 01:48PM
May-09-24 11:55PM
04:05PM Loading…
04:05PM
May-07-24 08:00AM
May-01-24 10:01AM
08:00AM
Apr-04-24 01:30AM
Mar-29-24 07:01PM
Mar-28-24 08:00AM
Mar-04-24 08:00AM
Mar-02-24 04:32AM
Feb-29-24 06:05PM
04:05PM
Feb-12-24 08:00AM
Feb-08-24 03:05AM
Feb-06-24 11:27PM
Feb-05-24 04:05PM
02:50PM
12:36PM
Feb-03-24 05:00PM
Jan-29-24 08:00AM
Jan-25-24 10:04PM
Jan-23-24 08:00AM
Jan-19-24 12:00PM
Jan-11-24 10:00AM
Jan-09-24 05:02AM
Jan-06-24 05:02AM
05:02AM
Jan-04-24 08:00AM
Jan-03-24 08:01AM
Dec-21-23 08:00AM
Dec-04-23 08:00AM
Nov-15-23 08:00AM
Nov-09-23 04:19PM
Nov-01-23 04:00PM
Oct-30-23 08:00AM
Oct-26-23 09:56AM
Oct-25-23 08:00AM
Oct-23-23 08:00AM
Sep-12-23 04:05PM
Sep-07-23 04:05PM
08:00AM
Aug-09-23 06:15PM
04:05PM
08:22AM
Jul-29-23 12:00PM
Jul-17-23 04:05PM
Jul-10-23 07:30PM
Jun-08-23 09:53AM
Jun-07-23 04:10PM
Jun-01-23 08:00AM
May-24-23 08:00AM
May-13-23 08:27AM
May-12-23 06:02PM
06:02PM
May-11-23 08:00AM
May-10-23 05:55PM
04:05PM
May-09-23 04:05PM
08:25AM
May-08-23 04:05PM
06:27AM
May-04-23 09:04PM
04:08PM
Apr-27-23 04:29PM
07:00AM
Apr-24-23 08:00AM
08:00AM
Apr-14-23 04:23AM
Apr-13-23 08:00AM
Apr-12-23 08:21AM
Mar-24-23 06:30AM
4DMT operates as a clinical-stage genetic medicines company focused on inventing and developing genetic medicines to treat large market diseases in ophthalmology, pulmonology and cardiology. It develops genetic medicines using its proprietary invention platform, Therapeutic Vector Evolution. It combines the power of the Nobel Prize-winning technology, directed evolution, with approximately one billion synthetic AAV capsid-derived sequences. Its product design, development and manufacturing engine create a valuable and diverse product pipeline. The company is currently advancing five clinical-stage and two preclinical product candidates, each tailored to address rare and large market diseases. 4DMT was founded by David H. Kirn, Melissa Kotterman, Theresa Janke, and David Schaffer on September 12, 2013 and is headquartered in Emeryville, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Bizily ScottChief Legal OfficerSep 16 '24Option Exercise6.495003,2457,281Sep 18 05:46 PM
Bizily ScottChief Legal OfficerSep 16 '24Sale16.335008,1656,781Sep 18 05:46 PM
Bizily ScottChief Legal OfficerAug 19 '24Option Exercise6.495003,2457,281Aug 21 04:28 PM
Bizily ScottChief Legal OfficerAug 19 '24Sale15.005007,5006,781Aug 21 04:28 PM
Bizily ScottChief Legal OfficerJul 16 '24Option Exercise7.601,75013,2958,531Jul 18 08:22 PM
Bizily ScottChief Legal OfficerJul 16 '24Sale27.111,75047,4426,781Jul 18 08:22 PM
Bizily ScottChief Legal OfficerJul 11 '24Option Exercise15.781,99631,4978,777Jul 15 06:13 PM
Bizily ScottChief Legal OfficerJul 11 '24Sale25.001,99649,9006,781Jul 15 06:13 PM
Kirn DavidChief Executive OfficerJul 10 '24Option Exercise14.5512,923188,0771,072,076Jul 12 05:46 PM
Kirn DavidChief Executive OfficerJul 10 '24Sale22.4912,923290,5981,059,153Jul 12 05:46 PM
Bizily ScottChief Legal OfficerJul 01 '24Option Exercise7.554,24832,0895,985Jul 03 05:11 PM
Bizily ScottChief Legal OfficerJul 01 '24Sale21.364,24890,7581,737Jul 03 05:11 PM
Kirn DavidChief Executive OfficerJun 24 '24Option Exercise14.4212,930186,4511,072,083Jun 26 05:07 PM
Kirn DavidChief Executive OfficerJun 24 '24Sale23.1012,930298,7111,059,153Jun 26 05:07 PM
Bizily ScottChief Legal OfficerJun 17 '24Option Exercise7.601,75013,2953,487Jun 20 04:59 PM
Bizily ScottChief Legal OfficerJun 17 '24Sale23.711,75041,4941,737Jun 20 04:59 PM
Bizily ScottChief Legal OfficerMay 16 '24Option Exercise7.601,75013,2953,487May 20 08:35 PM
Bizily ScottChief Legal OfficerMay 16 '24Sale25.451,75044,5411,737May 20 08:35 PM
Bizily ScottChief Legal OfficerApr 16 '24Option Exercise7.601,75013,2953,487Apr 18 08:48 PM
Bizily ScottChief Legal OfficerApr 16 '24Sale25.741,75045,0451,737Apr 18 08:48 PM
Bizily ScottChief Legal OfficerApr 01 '24Option Exercise12.548,153102,2249,890Apr 03 07:18 PM
Bizily ScottChief Legal OfficerApr 01 '24Sale31.788,153259,1021,737Apr 03 07:18 PM
Bizily ScottChief Legal OfficerMar 27 '24Option Exercise25.985,833151,5417,570Mar 29 04:52 PM
Bizily ScottChief Legal OfficerMar 27 '24Sale35.045,833204,4101,737Mar 29 04:52 PM
Bizily ScottChief Legal OfficerMar 18 '24Option Exercise7.601,75013,2953,487Mar 20 04:40 PM
Bizily ScottChief Legal OfficerMar 18 '24Sale31.271,75054,7221,737Mar 20 04:40 PM
Bizily ScottChief Legal OfficerFeb 27 '24Option Exercise20.241,90938,6383,646Feb 29 06:01 PM
Bizily ScottChief Legal OfficerFeb 27 '24Sale30.001,90957,2701,737Feb 29 06:01 PM
Bizily ScottChief Legal OfficerFeb 16 '24Option Exercise7.601,75013,2953,487Feb 21 05:41 PM
Bizily ScottChief Legal OfficerFeb 16 '24Sale27.671,75048,4221,737Feb 21 05:41 PM
Bizily ScottChief Legal OfficerFeb 08 '24Option Exercise10.186,24463,5864,653Feb 12 09:04 PM
Bizily ScottChief Legal OfficerFeb 08 '24Sale27.506,244171,7101,737Feb 12 09:04 PM
Kirn DavidChief Executive OfficerFeb 08 '24Sale27.1392,0012,495,8221,059,153Feb 12 08:22 PM
Kim Robert YoungChief Medical OfficerFeb 05 '24Option Exercise15.2924,000366,84013,595Feb 07 08:32 PM
Kim Robert YoungChief Medical OfficerFeb 05 '24Sale30.0524,552737,7881,043Feb 07 08:32 PM
Kirn DavidChief Executive OfficerJan 23 '24Sale18.415,696104,8511,151,154Jan 25 04:59 PM
Kirn DavidChief Executive OfficerJan 04 '24Sale20.3140,732827,2021,185,087Jan 08 04:19 PM
Kirn DavidChief Executive OfficerJan 05 '24Sale19.5728,237552,4781,156,850Jan 08 04:19 PM
Kirn DavidChief Executive OfficerDec 15 '23Sale17.2728,632494,4321,230,521Jan 08 04:19 PM
Kirn DavidChief Executive OfficerDec 18 '23Sale18.134,70285,2431,225,819Jan 08 04:19 PM
VIKING GLOBAL INVESTORS LP10% OwnerJan 04 '24Sale19.53540,00010,546,2004,247,914Jan 05 05:44 PM